Literature DB >> 11878826

Inhibition of murine corneal allograft rejection by treatment with antibodies to CD80 and CD86.

Fumie Kagaya1, Junko Hori, Kazutaka Kamiya, Yuichi Kaji, Tetsuro Oshika, Shiro Amano, Satoru Yamagami, Tadahiko Tsuru, Sumiyoshi Tanaka, Hironori Matsuda, Hideo Yagita, Ko Okumura.   

Abstract

The purpose of this study was to investigate the role of CD80 and CD86 costimulatory molecules in corneal allograft rejection. Anti-CD80 and anti-CD86 monoclonal antibodies (mAbs) were administered after orthotopic corneal allograft transplantation. Graft rejection was observed by biomicroscopy. Population and localization of CD80(+)and CD86(+)cells in the cornea, cervical lymph nodes, and spleen were examined by flow cytometry and immunohistochemistry. The combined use of anti-CD80 and anti-CD86 mAbs was effective in prolonging corneal allograft survival. In the untreated mice bearing rejected graft, many CD86(+)and CD80(+)cells were found around the host-graft junctional area in the cornea, and CD86(high)cells were found in the cervical lymph node and spleen. In contrast, few CD86(+)or CD80(+)cells were observed in the cornea, cervical lymph node, and spleen from the mice treated with anti-CD80/CD86 mAbs. These results demonstrated a significant role of CD80 and CD86 costimulatory molecules in corneal allograft rejection. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11878826     DOI: 10.1006/exer.2001.1109

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  8 in total

1.  Ballistic CTLA4 and IL-4 gene transfer into the lower lid prolongs orthotopic corneal graft survival in mice.

Authors:  Er-Ping Zhang; Jürgen Franke; Matthias Schroff; Claas Junghans; Burghardt Wittig; Friedrich Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-10-18       Impact factor: 3.117

2.  Ipsilateral submandibular lymphadenectomy does not prolong orthotopic corneal graft survival in mice.

Authors:  Felix Schulte; Er-Ping Zhang; Jürgen Franke; Ralf Ignatius; Friedrich Hoffmann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-11-14       Impact factor: 3.117

3.  Blockade of the 4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways promotes corneal allograft survival in mice.

Authors:  Tatsuhiko Asai; Beom K Choi; Patrick M Kwon; Won Y Kim; Jung D Kim; Dass S Vinay; Bryan M Gebhardt; Byoung S Kwon
Journal:  Immunology       Date:  2007-03-22       Impact factor: 7.397

Review 4.  Therapeutic approaches for induction of tolerance and immune quiescence in corneal allotransplantation.

Authors:  Maryam Tahvildari; Afsaneh Amouzegar; William Foulsham; Reza Dana
Journal:  Cell Mol Life Sci       Date:  2018-01-06       Impact factor: 9.261

Review 5.  Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.

Authors:  Tulio B Abud; Antonio Di Zazzo; Ahmad Kheirkhah; Reza Dana
Journal:  J Ophthalmic Vis Res       Date:  2017 Jan-Mar

6.  Cyclosporine a drug-delivery system for high-risk penetrating keratoplasty: Stabilizing the intraocular immune microenvironment.

Authors:  Ting Zhang; Zhiyuan Li; Ting Liu; Suxia Li; Hua Gao; Chao Wei; Weiyun Shi
Journal:  PLoS One       Date:  2018-05-07       Impact factor: 3.240

Review 7.  Corneal Allografts: Factors for and against Acceptance.

Authors:  Justyna Sakowska; Paulina Glasner; Maciej Zieliński; Piotr Trzonkowski; Leopold Glasner
Journal:  J Immunol Res       Date:  2021-10-03       Impact factor: 4.818

8.  Anti-CD80/86 antibodies inhibit inflammatory reaction and improve graft survival in a high-risk murine corneal transplantation rejection model.

Authors:  Jun Zhu; Takenori Inomata; Masahiro Nakamura; Keiichi Fujimoto; Yasutsugu Akasaki; Kenta Fujio; Ai Yanagawa; Koichiro Uchida; Jaemyoung Sung; Naoko Negishi; Ken Nagino; Yuichi Okumura; Maria Miura; Hurramhon Shokirova; Mizu Kuwahara; Kunihiko Hirosawa; Akie Midorikawa-Inomata; Atsuko Eguchi; Tianxiang Huang; Hideo Yagita; Sonoko Habu; Ko Okumura; Akira Murakami
Journal:  Sci Rep       Date:  2022-03-22       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.